OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Matulonis on the Results of the Phase 3 SORAYA Trial in Platinum-Resistant Ovarian Cancer

March 21st 2022

Ursula A. Matulonis, MD, discusses the results of the phase 3 SORAYA trial in platinum-resistant ovarian cancer.

Dr. Lara on Role of Molecular Differences in Disparities in Uterine Serous Carcinoma

March 21st 2022

Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.

Dr. Shereck Highlights a Day In the Life of an Attending Physician

March 21st 2022

Evan B. Shereck, MD, MEd, serves as professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University. In this episode, she highlights the average work day as an attending physician.

Dr. Shereck Shares How She Makes Medical Education More Fun and Accessible

March 21st 2022

Evan B. Shereck, MD, MEd, serves as professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University. In this episode, she expands on her process for making medical education more accessible.

Dr. Shereck Highlights Her Path to Becoming a Fellowship Director

March 21st 2022

Dr. Shereck Shares How She Found Her Place in Pediatric Oncology

March 21st 2022

Evan B. Shereck, MD, MEd, professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University, discusses how she works to "gamify" medical education.

Dr. Shereck Discusses Falling in Love With Pediatric Oncology

March 21st 2022

Dr. Shereck Discusses Helping Oncology Fellows Find a Career

March 21st 2022

Evan B. Shereck, MD, MEd, serves as professor of pediatrics, Division of Hematology and Oncology, School of Medicine; program director, Pediatric Hematology/Oncology Fellowship; associate director, Cancer Research Training, Knight Cancer Institute; and block co-director, Blood and Host Defense at Oregon Health & Science University. In this episode, she discusses how she helps her fellows navigate their career goals.

Dr. Zakhour on the Utilization of Tisotumab Vedotin in Cervical Cancer

March 19th 2022

Mae Zakhour, MD, discusses the utilization of tisotumab vedotin-tftv in cervical cancer.

Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma

March 19th 2022

Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma

Dr. Tawbi on the FDA Approval of Relatlimab/Nivolumab in Unresectable or Metastatic Melanoma

March 18th 2022

Hussein A. Tawbi, MD, PhD, discusses the FDA approval of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Dr. Abid on the Efficacy of a Third COVID-19 Vaccine Dose After Hematopoietic Cell

March 17th 2022

Muhammad Bilal Abid, MD, MRCP, discusses the efficacy of a third COVID-19 vaccine dose after hematopoietic cell transplantation in patients with hematologic malignances.

Dr. Santos on the Utilization of Approved Monotherapies in NSCLC

March 17th 2022

Edgardo S. Santos, MD, FACP, discusses the utilization of approved monotherapies in non–small cell lung cancer.

Dr. Socinski on Treatment Considerations for Difficult-to-Treat Patients in Lung Cancer

March 17th 2022

Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.

Dr. Tagawa on Utilizing Bone-Targeting Radium-223 in Prostate Cancer

March 16th 2022

Scott T. Tagawa, MD, MS, FACP, discusses the use of radium-223 in prostate cancer.

Dr. Dreicer on the Impact of the CHAARTED Trial in mCSPC

March 16th 2022

Robert Dreicer, MD, discusses the impact of the phase 3 CHAARTED trial in metastatic castration-sensitive prostate cancer.

Dr. Sallman on the Role of Uproleselan in Targeting E-Selectin in AML

March 16th 2022

David Sallman, MD, discusses the role of uproleselan (GMI-1271) when utilized in acute myeloid leukemia.

Dr. Iacovelli on Next Steps of the ARIES Trial in Urothelial Cancer

March 15th 2022

Roberto Iacovelli, MD, PhD, discusses the potential next steps of the phase 2 ARIES trial in urothelial cancer.

Dr. Olawaiye on Front Line Treatment Sequencing Considerations in Ovarian Cancer

March 15th 2022

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

Dr. Ansell on the Evolving Treatment Landscape in DLBCL

March 15th 2022

Stephen M. Ansell, MD, PhD, discusses the evolving treatment landscape in diffuse large B-cell lymphoma.